By Deandrea Hamilton
Editor
#TurksandCaicos, January 20, 2022 – Five medical treatments for Covid-19 patients are in use in the United Kingdom according to National Health Service, (NHS) yet Turks and Caicos has employed only one Covid-19 therapeutic and with the surge in new deaths due to the virus, it is a wonder if more can be done in this country to save lives.
Dexamethasone was approved by the NHS in June 2020, less than a month later, Turks and Caicos Hospitals began use of the therapeutic said to offer ground-breaking coronavirus treatment.
“Dexamethasone, an anti-inflammatory drug, has been immediately approved to treat all UK hospitalised COVID-19 patients requiring oxygen, including those on ventilators, from today.
The drug has been proven to reduce the risk of death significantly in COVID-19 patients on ventilation by as much as 35% and patients on oxygen by 20%, reducing the total 28-day mortality rate by 17%,” informed a media statement from the NHS on June 16, 2020.
Ever so quietly, and despite repeated media questions to the Ministry of Health about therapeutics, Dexamethasone was added to the Covid-19 response arsenal without a word.
The TCI Hospitals informed of its use late 2021, due to Magnetic Media questions on the issue.
However, that is where the list of therapeutics ends. But not so for the UK, from whom Turks and Caicos is taking medical cues.
Four other therapies are employed in the United Kingdom in an effort to save lives; they are: Tocilizumab and sarilumab (for REHAB); Tocilizumab (for RECOVERY); Inhaled budesonide (for PRINCIPLE care) and Ronapreve (for RECOVERY).
No surprise the effort is varied and fervent as the UK sadly reports one of the highest death tolls to COVID in the world at 153,000 people lost to the virus.
By January 2021, the UK, which was also the first country to approve emergency use of the Covid-19 vaccines, added a new drug: Tocilizumab and sarilumab.
Tocilizumab and sarilumab is administered to the sickest Covid-19 patients, said the NHS.
“This is a significant finding which could have immediate implications for the sickest patients with COVID-19,” said Professor Anthony Gordon, Chair in Anaesthesia and Critical Care at Imperial College London and a Consultant in Intensive Care Medicine at Imperial College Healthcare NHS Trust.
“We found that among critically ill adult patients – those receiving breathing support in intensive care – treatment with these drugs can improve their chances of survival and recovery,” explained Professor Gordon. “At a time when hospitalisations and deaths from COVID-19 are soaring in the UK, it’s crucial we continue to identify effective treatments which can help to turn the tide against this disease.”
A month later, a recovery version of Tocilizumab came on stream.
The NHS, which ran studies on all of the drugs before introducing them for medical care to its residents reported that: “Treatment with tocilizumab significantly reduced deaths: 596 (29%) of the patients in the tocilizumab group died within 28 days compared with 694 (33%) patients in the usual care group (rate ratio 0·86; [95% confidence interval [CI] 0·77 to 0·96]; p=0·007), an absolute difference of 4%. This means that for every 25 patients treated with tocilizumab, one additional life would be saved.”
By April 2021, the UK was offering a therapeutic which was administered to people presenting with COVID but not yet hospitalised for the virus.
Inhaled budesonide, was given before Covid-19 turned severe.
“This asthma drug shortens recovery time said the National Health Service. The statement published on April 12, 2021 said, “Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants. The drug is now available to treat COVID-19 on a case-by-case basis in UK primary care.”
The final approved “effective treatment” listed on the UK Government’s website is Ronapreve, sanctioned as effective in September 2021.
It was geared to health care workers without coronavirus antibodies and those 12 to 49, who are considered
immunocompromised.
Health and Social Care Secretary Sajid Javid said: “We have secured a brand new treatment for our most vulnerable patients in hospitals across the UK and I am thrilled it will be saving lives from as early as next week.
The UK is leading the world in identifying and rolling out life-saving medicines, particularly for COVID-19, and we will continue our vital work to find the best treatments available to save lives and protect the NHS.
Ronapreve is the first neutralising antibody medicine specifically designed to treat COVID-19 to be authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in the UK.”
Given the Turks and Caicos, as a UK Overseas Territory has been extraordinarily supported from the onset of the pandemic by the United Kingdom, it is unclear why only one of five options, approved by Mother England has been activated locally.
While all messages from the NHS reveal a zeal to have as many possible options for the people of the UK in the fight against COVID-19. Turks and Caicos seems stuck and lacking the motivation it needs to offer more life-saving treatments to the people – vaccinated or unvaccinated – of the territory.
Perhaps the knowledge of the cold corpses of six beloved people from January 2022 deaths due to COVID, including a special needs young woman, may get the government spending public money on the other drugs and treatments, which give Covid-19 patients an extra fighting chance at life.